Sign Out
Before initiating therapy with this medicine, careful enquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens.
Avoid this medicine if infectious mononucleosis is suspected since the occurrence of a morbilliform rash has been associated with this condition following the use of amoxicillin.
Prolonged use may also occasionally result in overgrowth of non-susceptible organisms.
Pseudomembranous colitis has been reported with the use of antibiotics and may range in severity form mild to life-threatening. Therefore, it is important to consider its diagnosis in patients who develop diarrhea during or after antibiotic use. If prolonged or significant diarrhea occurs or the patient experiences abdominal cramps, treatment should be discontinued immediately and the patient investigated further.
Appropriate monitoring should be undertaken when anticoagulants are prescribed concurrently and adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation. Abnormal prolongation of prothrombin time has been reported rarely in patients receiving this medicine and oral anticoagulants.
Should be used with caution in patients with evidence of hepatic dysfunction. Changes in liver function tests have been observed in some patients receiving this medicine.
Cholestatic jaundice, which may be severe, but is usually reversible, has been reported rarely. Signs and symptoms may not become apparent for up to six weeks after treatment has ceased.
Not recommended in patients with renal impairment.
In patients with reduced urine output, crystalluria has been observed very rarely, predominantly with parenteral therapy. During the administration of high doses of amoxicillin, it is advisable to maintain adequate fluid intake and urinary output in order to reduce the possibility of amoxicillin crystalluria.
This product contains aspartame, therefore care should be taken in patients with phenylketonuria.
Continue with Google